medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

SPECIFIC DETECTION OF SARS-COV-2 B.1.1.529 (OMICRON) VARIANT BY FOUR RT-qPCR DIFFERENTIAL ASSAYS

Oran Erster[1§], Adi Beth-Din[2], Hadar Asraf[1], Virginia Levy[1], Areej Kabat[1], Batya Mannasse[1], Roberto Azar[1], Ohad Shifman[2], Shirley Lazar[2], Michal Mandelboim,[1,3], Shay Fleishon[1], Ella Mendelson[1,3], Neta S Zuckerman[1]

[1]Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel.
[2]Israel Institute for Biological Research
[3]School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
[§]Corresponding author contact information: oran.erster@sheba.health.gov.il

Abstract

In this report, we describe four RT-qPCR assays that enable rapid identification of the newly emerging SARS-COV-2 Omicron (B.1.1.529) variant of concern. The assays target Omicron characteristic mutations in the nsp6 (Orf1a), spike and nucleocapsid genes. We demonstrate that the assays are straightforward to assemble and perform, are amendable for multiplexing, and may be used as a reliable first-line tool to identify B.1.1.529 suspected samples. Importantly, this is a preliminary development report. Further validation and optimization of the assays described herein will be published hereafter.

Key words: SARS-COV-2, B.1.1.529 VOC Omicron, RT-qPCR, differential assay

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1. Introduction

The SARS-COV-2 (SC-2) B.1.1.529 (Omicron) variant recently emerged in South Africa and Botswana in November 2021, and was identified in numerous countries worldwide shortly after, with travel-related cases identified in Hong Kong, Belgium and Israel at the end of November. The Omicron variant includes 30 mutations in the spike protein alone, 15 of which are in the receptor binding domain (RBD). Being the most highly divergent SARS-CoV-2 variant yet, this newly emerging variant of concern (VOC) is suspected to have a potential for increased transmissibility and reduced vaccine effectiveness.

Due to the urgent need to provide a first-line approach for specific detection of the Omicron variant, we describe here the preliminary development of four assays that provide rapid identification of suspected Omicron variant samples. The assays were developed by the Israel Ministry of Health Central Virology Laboratory (CVL) and the Israel Institute for Biological Research (IIBR). Some of the reactions in these assays partially rely on established protocols, and enable the detection of mutations that are thus far strongly associated with this variant, based on sequences available in the GISAID database (www.epicov.org/epi3/frontend#5c1e82). The assays were tested with the first Omicron samples identified in Israel and their optimization is currently underway. Since the only circulating variant in Israel is currently B.1.617 (Delta), the specificity of the assays was initially tested using this variant as a reference. In some cases, the assay performance was also tested using the A19 ("WT") and B.1.1.7 (Alpha) strains. All B.1.1.529 specific reactions were performed in a duplex with the E-sarbeco reaction described by Corman et al. (1), with some modifications that were described previously (2) to render the reaction more suitable for multiplexing. The negative N_{del} reaction is based on the CDC N1 reaction, which is widely used in many diagnostic laboratories (3). The assays described herein can be implemented in any molecular diagnostic laboratory and do not require the use of specific brand instruments, or unique reagents.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2. Materials

2.1. Primers details

Primer name	Sequence 5'->3'	Reference
N_{del} positive detection		
28322 Fwd	TTTGGTGGACCCTCAGATTC	This study
28424 Rev	CGCAGTATTATTGGGTAAACCTTG	This study
28354 probe	CCAGAATGGTGCGGCGCGATC	This study
N_{del} negative detection		
2019-nCoV_N1-F1a	CTAAACGAACAAACTAAAATGTCTG	This study
2019-nCoV_N1-R1a	GCCCCACTGCGTTCTCCATTC	US CDC[a]
2019-nCoV_N1-P	ACCCCGCATTACGTTTGGTGGACC	This study
S_{indel} reaction		
22174 Fwd	GTTATTTTAAAATATATTCTAAGCACACG	This study
22248 Rev	TAAAGCCGAAAAACCCTGAG	This study
22206 probe	ATTATAGTGCGTGAGCCAGAAGATCTCC	This study
Nsp6 deletion reaction		
11248 B529 Fwd	ATATGGTTGATACTAGTTTTAAGC	This study
COV19_11310_P	CTGTGTTATGTATGCATCAGCTGTAGT	This study
COV19_11344_R	ACACAGTTCTTGCTGTCATAAGG	This study
E-sarbeco reaction		
E_Sarbeco_F1b	GTTAATAGCGTACTTCTTTTTCTTGC	Corman *et al*.[b]
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	Corman *et al.*
E_Sarbeco_P1	ACACTAGCCATCCTTACTGCGCTTCG	Corman *et al*.

[a]https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.

[2]https://doi.org/10.1128/Spectrum.00506-21.

2.2. Master mix

The SensiFast Lo-ROX probe 1-step PCR mix was used (*https://www.bioline.com/sensifast-probe-lo-rox-kit.html*).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2.3.Positive N_{del} Reaction setup

Positive N_{del} reaction		Volume (µl) per reaction
Master Mix SensiFast Probe Lo-ROX One-Step	Conc / Rxn	12.5
H_2O		1.8
E-Sarbeco-F1b 40µM	600nM	0.375
E-Sarbeco-R 40µM	600nM	0.375
E-Sarbeco-P 20µM FAM	300nM	0.375
COV19_28322Fwd_F 40uM stock	600nM	0.375
COV19_28412 Rev 40uM	600nM	0.375
COV19_22206_P 20uM HEX	300nM	0.375
SensiFast RT-Enzyme		0.25
RNAse inhibitor		0.2
Total		17
RNA		8

2.4. Negative N_{del} reaction setup

N_{del} negative reaction		Volume (µl) per reaction
Master Mix SensiFast Probe Lo-ROX One-Step	Conc / Rxn	12.5
H_2O		1.8
E-Sarbeco-F1b 40µM	600nM	0.375
E-Sarbeco-R 40µM	600nM	0.375
E-Sarbeco-P 20µM FAM	300nM	0.375
CDC N1 Fwd 40uM stock	600nM	0.375
N1 R1a Rev 40uM	600nM	0.375
CDC N1 probe 20uM HEX	300nM	0.375
SensiFast RT-Enzyme		0.25
RNAse inhibitor		0.2
Total		17
RNA		8

2.5. $S_{22194\ indel}$ reaction

$S_{22194\ indel}$ reaction	Volume (µl) per reaction
Master Mix SensiFast Probe Lo-ROX One-Step	12.5
H_2O	1.8
E-Sarbeco-F1b 40µM	0.375
E-Sarbeco-R 40µM	0.375
E-Sarbeco-P 20µM TXRed	0.375
22174 Fwd 40µM	0.375
22248 Rev 40µM	0.375
22206 probe 20µM	0.375
SensiFast RT-Enzyme	0.25
RNAse inhibitor	0.2
Total	17
RNA	8

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2.6. $NSP6_{del}$ reaction

$NSP6_{del}$ **reaction**		**Volume (µl) per reaction**
Master Mix SensiFast Probe Lo-ROX One-Step	**Conc / Rxn**	**12.5**
H_2O		**1.8**
E-Sarbeco-F1b 40µM	**600nM**	**0.375**
E-Sarbeco-R 40µM	**600nM**	**0.375**
E-Sarbeco-P 20µM FAM	**300nM**	**0.375**
11248 B529 Fwd	**600nM**	**0.375**
COV19_11344_R	**600nM**	**0.375**
COV19_11310_P	**300nM**	**0.375**
SensiFast RT-Enzyme		**0.25**
RNAse inhibitor		**0.2**
Total		**17**
RNA		**8**

2.7. Thermal profile

All reactions were run in a Bio-Rad CFX96 instrument, with the same thermal profile, as follows: (1) 45.0°C for 10'10", (2) 95.0°C for 2'20", 45X[(3) 95.0°C for 4", (4) 60.0°C for 20"]. Fluorescence was read at step (4). For all assays except the $S_{22194\ indel}$ duplex reaction, fluorescence was read in the FAM and HEX/VIC channels. For the $S_{22194\ indel}$ reaction, fluorescence was read in the FAM and Texas-Red (TXRed) channels.

2.8 Bioinformatic analysis

Sequences were obtained from the GISAID database (https://www.epicov.org/epi3/frontend#5c1e82) or from internal CVL sequencing of clinical samples. Global analysis was performed using the NextStrain analysis tools (https://nextstrain.org/ncov/gisaid/global). The qPCR reactions were designed using the Genenious software package (www.geneious.com).

3. Results

3.1. Phylogenetic analysis of Omicron-specific mutations

The deletion in the spike gene at positions 22194-22196 and the deletion in the N gene at positions 28,362-28,371 were identified by Nextstrain analysis (https://nextstrain.org/ncov/gisaid/global) as unique for Omicron (**Figure 1**). Multiple alignment of available Omicron

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

sequences obtained from GISAID (www.epicov.org/epi3/frontend#5c1e82) confirmed that the presence of these deletions, as well as the spike gene insertion in positions 221207-221215, were present in all sequenced Omicron samples. We therefore based our assays on these unique mutations.



Figure 1. Global phylogenetic analysis showing the uniqueness of the spike 22194-22196 deletion (A) and the nucleocapsid (N) 28362-28371 deletion (B). the analysis was performed using Nextstrain (https://nextstrain.org/ncov/gisaid/global), based on sequences from the GISAID database (www.epicov.org/epi3/frontend#5c1e82). The lineage in which these mutations occur is circulated with a highlighted circle.

3.2. Development of negative N_{del} reaction

The assay targets the deletion at position 28362 of reference sequence NC_045512. The selectivity of the assay is accomplished by using the N1 R1a revers primer. Its annealing is strongly inhibited (>104-fold inhibition) in the presence of the deletion, thereby resulting in either absence of signal, or a 12-15 Cq values difference between the inclusive E-sarbeco reaction and the negative N_{del} reaction. The advantage of this assay is the use of widely available primer and probe developed by the CDC (3). **Figure 2** shows the amplification curves generated by testing A19 ("WT"), B.1.1.7 (Alpha), B.1.617 (Delta) and the suspected Omicron samples using the duplex assay containing the inclusive E-sarbeco reaction and the specific negative N_{del} reaction. The Cq values of each sample are shown in **Table 1**.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. Amplification curves generated with the negative N_{del} reaction. (A) curves of suspected Omicron sample. (B) curves of a Delta sample.

Table 1. Cq values of each reaction for the different samples. The Cq difference between the Ndel reaction and the CoV19 reaction are shown in the "ΔCq" column.

Sample	Cov19 E	N_{del}	ΔCq
WT	30.43	31.44	1.01
Alpha	26.45	27.87	1.42
Delta	25.16	26.42	1.26
Omicron	23.38	37.96	14.58

3.3. Development of positive N_{del} reaction

In this reaction, the probe is annealing to the 9bp deletion at positions 28362-28371 of reference sequence NC_045512. Contrary to the negative N_{del} reaction, here the fluorescent signal is generated only in the presence of the deletion. **Figure 3** shows the amplification curves of serial dilutions of the first suspected Omicron sample obtained in Israel, and of A19, Alpha and Delta variant samples. **Table 2** details the Cq values obtained in this reaction.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. Amplification curves generated with the positive N_{del} reaction. (A) Serial dilutions of a suspected Omicron sample. (B) Clinical Delta samples. The curves of each reaction are indicated with corresponding arrows.

Table 2. Cq values obtained using the Positive N_{del} duplex assay.

Sample	Cov19 E	Positive N_{del}
Susp. Omicron 10E-3	25.88	25.20
Susp. Omicron 10E-4	29.12	28.45
Susp. Omicron 10E-5	32.37	31.02
Susp. Omicron 10E-6	37.33	41.03
Delta 1	20.37	
Delta 2	19.62	
Delta 3	19.28	
Delta 4	21.47	
H_2O		
Neg RNA		

3.4. Development of the $S_{22194\ indel}$ reaction

This reaction targets the Omicron-unique deletion at positions 22194-22196 and insertion at positions 22207-22216 of reference sequence NC_045512. The probe in this reaction is complementary to the Omicron sequence and cannot bind to non-Omicron RNA. As described above, this assay was tested in a duplex with the SC-2 inclusive E-sarbeco reaction, testing the suspected Omicron sample and Delta samples. Figure 4 shows the resulting amplification curves and the Cq values are detailed in Table 3. It should be noted that these are preliminary results and the reaction should be further optimized for sensitivity and robustness. Its selectivity is, however, very specific and it allows clear identification of Omicron samples.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. Amplification curves of the $S_{22194\ indel}$ reaction. (A) curves of dilutions of the suspected Omicron sample. (B) curves of four Delta samples. The curves of each reaction are indicated with corresponding arrows.

Table 3. Cq values obtained with the $S_{22194\ indel}$ reaction.

Sample	$S_{22194\ indel}$	Cov19 E
Susp. B.1.1.529 10E-3	25.22	26.84
Susp. B.1.1.529 10E-4	27.19	30.07
Susp. B.1.1.529 10E-5	30.73	32.72
Susp. B.1.1.529 10E-6	41.89	36.18
Delta 1		21.21
Delta 2		21.07
Delta 3		20.57
Delta 4	44.94	23.13
H_2O		
Neg RNA		

3.5 Development of the NSP_{del} reaction

In this reaction, the forward primer is corresponding to the 9bp deletion at positions 11283-11292 of reference sequence NC_045512. When testing a deletion-positive sample, the Cq values obtained are similar to those obtained with the E-sarbeco reaction. In the absence of the deletion, the reaction is either completely, or strongly (>10^4-fold) inhibited. Importantly, this deletion was detected in the Alpha, B.1.351 (Beta) and P.1 (Gamma) variants. However, since currently the only circulating variant in Israel and worldwide is Delta, this assay is sufficiently specific for identifying Omicron-suspected samples in Israel. Examination of complete genome sequencing in Israel from the last 3 months shows ~0.03% incidence of this deletion in >3,000 examined samples (CVL unpublished data). Therefore, we assume that currently, this assay can be reliable in detecting

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Omicron-suspected samples. **Figure 5** shows the amplification curves of an Omicron-suspected sample, together with Alpha and Delta samples, tested with the E-sarbeco + $NSP6_{del}$ reactions duplex. As expected, both the Alpha and Omicron-suspected samples were positive for the presence of the NSP6 deletion. The Delta samples were either negative for the $NSP6_{del}$ reaction or weakly positive, with Cq difference of 12-14 cycles between the E reaction and the $NSP6_{del}$ reaction. The Cq values of each reaction are detailed in **Table 4**.



Figure 5. Amplification curves of the $NSP6_{del}$ reaction. (A) Curves of serial dilutions of a suspected Omicron sample. (B) amplification of an Alpha sample. (C) Curves of five Delta samples. The curves of each reaction are indicated with corresponding arrows.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 4. Cq values obtained for the examined samples in the E-sarbeco + $NSP6_{del}$ duplex assay. The Cq difference between the $NSP6_{del}$ reaction and the CoV19 reaction are shown in the "ΔCq" column.

Sample	COV19 E	$nsp6_{del}$	ΔCq
Susp. Omicron 10E-2	22.11	23.52	1.41
Susp. Omicron 10E-3	25.28	26.63	1.35
Susp. Omicron 10E-4	28.29	29.28	0.99
Susp. Omicron 10E-5	31.92	33.48	1.56
Susp. Omicron 10E-6	41.14	42.32	1.18
Alpha	15.02	16.14	1.12
Delta 1	23.89	36.45	12.56
Delta 2	26.9		
Delta 3	30.67		
Delta 5	20.4	34.12	13.72
Delta 6	27.06		
CO-NEGATIVE			

4. Discussion

The four assays described herein are designed to help diagnostic laboratories to rapidly identify samples as Omicron. These protocols are fast, readily amendable for up-scaling, and are far more simple and cost-effective compared with sequencing. The uniqueness of the mutations that the assays target render them highly accurate in identifying the suspected samples as Omicron, compared with other, less specific assays that detect more common mutations, such as the spike gene 69-70 deletion or the N501Y mutation. Indeed, the spike gene 69-70 deletion was found to exist in ~1% of imported or circulating variants in Israel in the past 3 months (CVL unpublished data). The development of these assays was performed with a very limited number of positive samples, obtained from the first Omicron-suspected cases in Israel, which were verified as Omicron via sequencing. It is important to note that these results are preliminary and warrant further optimization. Due to the urgent need to make such discriminatory assays available to the international community, we made an effort to publish them as quickly as possible. It should be noted that the GISAID comprehensive database was important for the completion of this task in such a short time. The assays should be sufficiently robust to be implemented with reaction mixes from different manufacturers, such as Takara, PCRBIO, Thermo-Fisher Taqpath, and others. Reactions adjustments should be made, however, in the thermal profile, according to the specifications of each such product.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267293; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We plan to conduct a far more thorough and comprehensive validation for these assays and publish our results in a proceeding report. We also welcome and comments and suggestions for improvements, should any such be available, from fellow laboratories.

Ethical Statement

This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). Patient consent was waived as the study used remains of clinical samples and the analysis used anonymous clinical data.

References

(1) Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25:2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.

(2) Erster O, Mendelson E, Levy V, Kabat, A, Mannasse B, Asraf H, Azar R, Ali Y, Shirazi R, Bucris E, Bar-Ilan D, Mor O, Mandelboim M, Sofer D, Fleishon S, Zuckerman NS. 2021. Rapid and high-throughput reverse transcriptase quantitative PCR (RT-qPCR) assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.351. Microbiol Spectr 9:e00506-21. https://doi.org/10.1128/Spectrum.00506-21.

(3) https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.